Monday 19 October 2026
Export PFSA’s income statement to Excel — free account
PROFUSA, Inc.
PFSA Healthcare Medical Devices
PROFUSA, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $100,000.00. In the quarter to June 2026, EPS grew 98.3%, free cash flow fell 359.3% and total debt fell 89.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.93
0.14
−13.08%
Follow PFSA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
0.13 | 0.08 | 0.01 | 0.03 | |
Current Ratio |
0.18 | 0.17 | 0.02 | 0.03 | |
Net Debt/EBITDA |
(0.78) | (3.38) | (1.11) | (1.74) | |
Debt/Assets |
471.20% | 366.28% | 557.66% | 494.53% | |
Debt/Equity |
(0.59) | (0.52) | (0.17) | (0.19) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.45 | 0.60 | 0.75 | 0.30 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (36.50) | |
Interest Coverage |
(13.47) | (3.09) | (51.36) | (1.05) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2,379.29) | (1,508.53) | (152.43) | (45.38) | |
Capex per Share |
(238.10) | (296.47) | 67.75 | (1.26) | |
Free Cash Flow per Share |
(2,617.38) | (1,805.00) | (84.67) | (46.64) | |
Cash per Share |
716.43 | 522.94 | 22.19 | 12.40 | |
Shareholders Equity per Share |
(8,085.71) | (7,840.59) | (1,668.52) | (467.71) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(8,085.71) | (7,840.59) | (1,668.52) | (467.71) | |
Free Cash Flow |
(10.99) | (6.14) | (1.43) | (2.70) | |
Working Capital |
(19.34) | (18.49) | (28.36) | (27.33) | |
Capital Expenditures |
(1.00) | (1.01) | 1.15 | (0.07) | |
Net Current Asset Value |
(34.01) | (26.67) | (28.40) | (27.33) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
3.85 | 6.15 | 4.62 | 4.80 | |
Average Assets |
6.52 | 3.42 | 1.42 | 1.50 | |
Average Common Equity |
(19.57) | (72.93) | (21.25) | (24.82) |
Columns are period end dates